Genotyping Panel for Psychotropic Medication Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selecting psychotropic medications lack precision, often leading to ineffective treatments due to variations in individual genetic responses, particularly with cytochrome P450 genes and neurotransmission genes, resulting in suboptimal patient outcomes.
Innovation Solution
A method involving genotyping patients for specific genes such as cytochrome P450 genes and serotonin transporter genes to tailor medication selection, using a panel of genes to correlate genetic profiles with medication metabolism and response, thereby guiding optimal medication choice.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional medication selection methods are used, then the process is simple and quick, but the treatment precision and patient response are poor
Solution Approach 1:
The patent segments the medication selection process into distinct genetic components: cytochrome P450 genes for metabolism assessment, neurotransmission genes for target assessment, and serotonin transporter genes for additional metabolic information. This segmentation allows comprehensive evaluation while maintaining organizational clarity and clinical applicability.
Solution Approach 2:
The patent creates a universal genotyping panel that can be applied across multiple psychotropic medication classes (antidepressants, antipsychotics, mood stabilizers) by assessing multiple gene families simultaneously. This multi-functional approach enables a single comprehensive test to guide medication selection for various drug types, reducing the need for separate assessments.
2Reliability
If a comprehensive genotyping panel is used, then treatment efficacy is improved, but the time and resources required for testing increase
Solution Approach 1:
The patent performs comprehensive genotyping assessments before medication initiation to identify the patient's metabolic phenotype and neurotransmission profile in advance. This preliminary action allows clinicians to select appropriate medications from the start, avoiding trial-and-error approaches and reducing the time to achieve effective treatment.
Solution Approach 2:
The patent combines multiple genetic assessments (cytochrome P450, neurotransmission, serotonin transporter genes) into a single integrated genotyping panel. This merging consolidates what would otherwise be separate testing procedures into one comprehensive test, reducing overall testing time and resources while providing holistic genetic information for medication selection.
3Object-affected harmful factors
If genetic variations are considered, then adverse reactions are reduced, but the complexity of medication selection increases
Solution Approach 1:
The patent applies local quality assessment by evaluating specific genetic regions relevant to medication metabolism and response. Rather than analyzing the entire genome, it focuses on specific cytochrome P450 genes, neurotransmission genes, and serotonin transporter genes that have known associations with psychotropic medication response, allowing targeted assessment of harmful factors without unnecessary complexity.
Solution Approach 2:
The patent uses genetic profiling as an intermediary tool that translates complex genetic variations into actionable clinical information. By assessing specific gene variants and their known associations with drug metabolism and response, the system mediates between raw genetic data and medication selection decisions, simplifying the clinical application while accounting for genetic complexity.
Data Source
AI summary
Methods for selecting a medication for a patient are described that include determining the patient's genotype for a panel of genes and selecting the medication based on the genotype. Articles of manufacture also are provided that include nucleic acid molecules for detecting alleles of genes encoding drug metabolizing enzymes and genes encoding products involved in neurotransmission.